{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:16:09Z","timestamp":1788196569883,"version":"build-2803163510"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,12]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in advanced malignancies but are frequently associated with immune-related adverse events. Vitiligo, a distinctive cutaneous immune-related adverse event, correlates with favorable prognosis in melanoma patients; however, its association with different ICI regimens and occurrence in nonmelanoma cancers remains inadequately characterized. We retrieved ICI-related vitiligo cases from the FDA Adverse Event Reporting System database between January 2015 and September 2025. Disproportionality analysis was performed using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker algorithms. The potential biological mechanisms underlying vitiligo induced by ICIs were examined using The Cancer Genome Atlas data. A total of 591 ICI-induced vitiligo cases were identified, wherein 358 (60.6%) and 177 (29.9%) were reported as anti-programmed cell death protein 1 and combination therapy. Combination therapy exhibited the highest crude incidence rate (0.57%), while anti-programmed death-ligand 1 monotherapy showed the lowest (0.06%). The ipilimumab\u2013pembrolizumab combination demonstrated the highest reporting odds ratio (97.2, 95% CI: 58.1\u2013162.4). Median time-to-onset varied significantly across ICI classes: anti-cytotoxic T-lymphocyte-associated protein 4 monotherapy (33 days), anti-programmed death-ligand 1 (50 days), combination therapy (61 days), and anti-programmed cell death protein 1 (72 days). Patients aged 65 to 79 years showed significantly delayed onset. Geographic analysis revealed prolonged time-to-onset in Asian patients versus Americans. Pan-cancer transcriptomic analysis demonstrated correlations between ICI-induced vitiligo and melanocyte development, innate immunity, and mitochondrial function. ICI-induced vitiligo exhibits significant heterogeneity in risk across treatment strategies, with combination therapy and anti-cytotoxic T-lymphocyte-associated protein 4 strategies conferring higher relative risks. Onset timing is substantially influenced by age and geographic factors. Integration of pharmacovigilance and transcriptomic data implicates coordinated effects of melanocyte-lineage antigens, innate immune and mitochondrial function pathways in vitiligo pathogenesis. This study aimed to systematically characterize the risk profile, onset timing, and potential biological mechanisms of ICI-induced vitiligo across different treatment strategies and cancer types.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049307","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:01:55Z","timestamp":1781600515000},"page":"e49307","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A real-world retrospective study of vitiligo associated with immune checkpoint inhibitors based on FAERS and TCGA databases"],"prefix":"10.1097","volume":"105","author":[{"given":"Jingchang","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Dermatology, Air Force Hospital of Southern Theatre Command, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Air Force Hospital of Southern Theatre Command, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Air Force Hospital of Southern Theatre Command, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Air Force Hospital of Southern Theatre Command, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Air Force Hospital of Southern Theatre Command, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Air Force Hospital of Southern Theatre Command, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingheng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260831","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy.","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"key":"R2-20260831","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy.","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"R3-20260831","doi-asserted-by":"crossref","first-page":"1752298","DOI":"10.3389\/fimmu.2026.1752298","article-title":"Neoadjuvant immunotherapy for lung cancer: current limitations and future prospects.","volume":"17","author":"Yang","year":"2026","journal-title":"Front Immunol"},{"key":"R4-20260831","doi-asserted-by":"crossref","first-page":"1757711","DOI":"10.3389\/fimmu.2026.1757711","article-title":"The impact of obesity-related systemic inflammation on the efficacy, toxicity, and biomarkers of immune checkpoint inhibitors in lung cancer: from mechanisms to clinical management.","volume":"17","author":"Cai","year":"2026","journal-title":"Front Immunol"},{"key":"R5-20260831","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaad.2022.12.048","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R6-20260831","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaci.2022.11.015","article-title":"Dermatologic immune-related adverse events to checkpoint inhibitors in cancer.","volume":"151","author":"Shah","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R7-20260831","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamadermatol.2024.5136","article-title":"Immune checkpoint inhibitor-induced vitiligo-like depigmentation.","volume":"161","author":"Starace","year":"2025","journal-title":"JAMA Dermatol"},{"key":"R8-20260831","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes.","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R9-20260831","doi-asserted-by":"crossref","first-page":"e009902","DOI":"10.1136\/jitc-2024-009902","article-title":"Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase.","volume":"12","author":"Noseda","year":"2024","journal-title":"J ImmunoTher Cancer"},{"key":"R10-20260831","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00403-023-02577-7","article-title":"Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management.","volume":"315","author":"Lo","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"R11-20260831","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/17435390.2026.2629809","article-title":"Unveiling the hidden risks of nanomedicine-based drug delivery: a comparative evaluation of drug safety profiles of liposomal irinotecan and conventional irinotecan.","volume":"20","author":"Zhang","year":"2026","journal-title":"Nanotoxicology"},{"key":"R12-20260831","doi-asserted-by":"crossref","first-page":"108044","DOI":"10.1016\/j.phrs.2025.108044","article-title":"A clinically relevant pan-cancer prognostic signature derived from T-cell activation immune genes: experimental validation across malignancies with emphasis on breast cancer.","volume":"222","author":"Zhang","year":"2025","journal-title":"Pharmacol Res"},{"key":"R13-20260831","doi-asserted-by":"crossref","first-page":"e20251717","DOI":"10.1084\/jem.20251717","article-title":"Immune checkpoint inhibitor-induced myocarditis is dependent on CD8 T cell-derived TNF and TNFR2 signaling.","volume":"223","author":"Warrick","year":"2026","journal-title":"J Exp Med"},{"key":"R14-20260831","doi-asserted-by":"crossref","first-page":"e13175","DOI":"10.1111\/dth.13175","article-title":"Efficacy of topical latanoprost in the treatment of eyelid vitiligo: a randomized, double-blind clinical trial study.","volume":"33","author":"Nowroozpoor Dailami","year":"2020","journal-title":"Dermatol Ther"},{"key":"R15-20260831","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4103\/ijdvl.IJDVL_790_18","article-title":"Nonsegmental vitiligo follows Blaschko\u2019s lines and embryonic pigmentary segments.","volume":"86","author":"Sarma","year":"2020","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R16-20260831","doi-asserted-by":"crossref","first-page":"1407894","DOI":"10.3389\/fphar.2024.1407894","article-title":"Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database.","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R17-20260831","doi-asserted-by":"crossref","first-page":"dkag060","DOI":"10.1093\/jac\/dkag060","article-title":"A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025.","volume":"81","author":"Frey","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"R18-20260831","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment.","volume":"23","author":"Wei","year":"2024","journal-title":"Mol Cancer"},{"key":"R19-20260831","doi-asserted-by":"crossref","first-page":"1684390","DOI":"10.3389\/fphar.2025.1684390","article-title":"Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS.","volume":"16","author":"Ma","year":"2025","journal-title":"Front Pharmacol"},{"key":"R20-20260831","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy.","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"R21-20260831","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1111\/jdv.20197","article-title":"Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.","volume":"39","author":"Godfrey","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R22-20260831","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.3390\/cimb46070430","article-title":"The latest look at PDT and immune checkpoints.","volume":"46","author":"Aebisher","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"R23-20260831","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/ijc.70159","article-title":"Immune checkpoint inhibitor-induced vitiligo: a large-scale real world pharmacovigilance study.","volume":"158","author":"Tang","year":"2026","journal-title":"Int J Cancer"},{"key":"R24-20260831","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.7150\/ijbs.93697","article-title":"Using combination therapy to overcome diverse challenges of immune checkpoint inhibitors treatment.","volume":"20","author":"Birnboim-Perach","year":"2024","journal-title":"Int J Biol Sci"},{"key":"R25-20260831","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"R26-20260831","doi-asserted-by":"crossref","first-page":"101550","DOI":"10.1016\/j.xcrm.2024.101550","article-title":"Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T cell senescence and cervical cancer recurrence.","volume":"5","author":"Dai","year":"2024","journal-title":"Cell Rep Med"},{"key":"R27-20260831","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43587-021-00082-y","article-title":"An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging.","volume":"1","author":"Sayed","year":"2021","journal-title":"Nat Aging"},{"key":"R28-20260831","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41598-024-84488-9","article-title":"Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients.","volume":"15","author":"Iwamoto","year":"2025","journal-title":"Sci Rep"},{"key":"R29-20260831","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1759-7714.14274","article-title":"Immune checkpoint inhibitor-related adverse events in lung cancer: real-world incidence and management practices of 1905 patients in China.","volume":"13","author":"Shi","year":"2022","journal-title":"Thorac Cancer"},{"key":"R30-20260831","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/0008-5472.CAN-03-2828","article-title":"Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells.","volume":"64","author":"Lengagne","year":"2004","journal-title":"Cancer Res"},{"key":"R31-20260831","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.immuni.2021.08.019","article-title":"Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma.","volume":"54","author":"Molodtsov","year":"2021","journal-title":"Immunity"},{"key":"R32-20260831","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/bjd.15651","article-title":"Paracrine regulation of melanogenesis.","volume":"178","author":"Yuan","year":"2018","journal-title":"Br J Dermatol"},{"key":"R33-20260831","doi-asserted-by":"crossref","first-page":"e012165","DOI":"10.1136\/jitc-2025-012165","article-title":"New insights into the role of IFN-\u03b1\/\u03b2 and TLR7\/8\/9 in cancer immunotherapy and systemic autoimmunity.","volume":"13","author":"Krieg","year":"2025","journal-title":"J ImmunoTher Cancer"},{"key":"R34-20260831","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.it.2010.01.002","article-title":"Crosstalk pathways between toll-like receptors and the complement system.","volume":"31","author":"Hajishengallis","year":"2010","journal-title":"Trends Immunol"},{"key":"R35-20260831","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s12967-023-04345-7","article-title":"An Fgr kinase inhibitor attenuates sepsis-associated encephalopathy by ameliorating mitochondrial dysfunction, oxidative stress, and neuroinflammation via the SIRT1\/PGC-1\u03b1 signaling pathway.","volume":"21","author":"Liu","year":"2023","journal-title":"J Transl Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:01:35Z","timestamp":1788195695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":35,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049307","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"2026-03-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}